Cyclacel Pharmaceuticals Gestione
Gestione criteri di controllo 3/4
We currently do not have sufficient information about the CEO.
Informazioni chiave
Spiro Rombotis
Amministratore delegato
US$661.0k
Compenso totale
| Percentuale dello stipendio del CEO | 84.7% |
| Mandato del CEO | 27.3yrs |
| Proprietà del CEO | 1.5% |
| Durata media del management | Nessun dato |
| Durata media del Consiglio di amministrazione | 8.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$18m |
| Mar 31 2024 | n/a | n/a | -US$20m |
| Dec 31 2023 | US$661k | US$560k | -US$23m |
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$24m |
| Mar 31 2023 | n/a | n/a | -US$23m |
| Dec 31 2022 | US$764k | US$546k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$20m |
| Dec 31 2021 | US$1m | US$531k | -US$19m |
| Sep 30 2021 | n/a | n/a | -US$20m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$1m | US$531k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$8m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$1m | US$531k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$8m |
| Jun 30 2019 | n/a | n/a | -US$8m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$753k | US$531k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$14m |
| Mar 31 2018 | n/a | n/a | -US$15m |
| Dec 31 2017 | US$776k | US$531k | -US$15m |
Compensazione vs Mercato: Spiro's total compensation ($USD661.05K) is about average for companies of similar size in the US market ($USD655.65K).
Compensazione vs guadagni: Spiro's compensation has been consistent with company performance over the past year.
AMMINISTRATORE DELEGATO
Spiro Rombotis (65 yo)
27.3yrs
Mandato
US$661,049
Compensazione
Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Pharmaceuticals, Inc. (formerly known as Cyclacel Group plc)) since August 1997 and has been its Founding C...
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 18.7yrs | US$661.05k | 1.52% $ 18.8k | |
| Executive VP of Finance | 18.7yrs | US$352.62k | 0.82% $ 10.2k | |
| Chief Medical Officer & Director | 3.9yrs | US$84.49k | 0.85% $ 10.5k | |
| Independent Chair of the Board | 10.2yrs | US$97.99k | 0.21% $ 2.6k | |
| Independent Director | 18.7yrs | US$136.99k | 0.21% $ 2.6k | |
| Independent Director | 4yrs | US$95.49k | 0.21% $ 2.6k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Vice Chairman | 6.2yrs | US$115.99k | 0.21% $ 2.6k | |
| Independent Director | 2.4yrs | US$85.49k | 0.20% $ 2.4k |
8.2yrs
Durata media
68yo
Età media
Consiglio di amministrazione esperto: CYCC.P's board of directors are considered experienced (8.2 years average tenure).